BECLOMETASONE/FORMOTEROL/GLYCOPYRRONIUM VS. FIXED AND OPEN COMBINATIONS OF INHALED CORTICOSTEROIDS, LONG-ACTING B2-AGONIST, AND LONG-ACTING MUSCARINIC ANTAGONIST IN ADULTS WITH UNCONTROLLED ASTHMA: A NETWORK META-ANALYSIS

被引：0
|
作者：
Orlovic, M. [1 ]
Nikolaidis, G. [2 ]
Tzelis, D. [3 ]
Barouma, I [3 ]
Vele, A. [1 ]
Kots, M. [1 ]
van der Deijl, M. [1 ]
Madoni, A. [4 ]
机构：
[1] Chiesi Farmaceutici Spa, Parma, PR, Italy
[2] IQVIA, London, England
[3] IQVIA Ltd, Athens, Attica, Greece
[4] Chiesi Farmaceutici Spa, Parma, PR, Italy
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE556
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Long-Acting β-Agonist/Long-Acting Muscarinic Antagonist Combinations Compare to Long-Acting β-Agonist/Inhaled Corticosteroid Combinations: A Network Meta-Analysis
    Ahmed, T. Said
    Al-Sarie, M.
    Srour, K.
    Rygielski, S.
    Ye, F.
    Hernandez, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [2] COMPARISON OF "OPEN TRIPLE" COMBINATIONS OF INHALED LONG-ACTING MUSCARINIC ANTAGONIST, LONG-ACTING B2-AGONIST AND AN INHALED CORTICOSTEROID IN PATIENTS WITH ASTHMA, COPD AND ASTHMA-COPD OVERLAP
    Mochizuki, Taichi
    Inoue, Yasushi
    Arai, Hiroyuki
    Ueda, Ryuta
    Nagase, Seisuke
    Umeda, Akira
    Tsushima, Kenji
    RESPIROLOGY, 2019, 24 : 162 - 163
  • [3] Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis
    Oba, Yuji
    Sarva, Siva T.
    Dias, Sofia
    THORAX, 2016, 71 (01) : 15 - 25
  • [4] A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
    Sion K.Y.J.
    Huisman E.L.
    Punekar Y.S.
    Naya I.
    Ismaila A.S.
    Pulmonary Therapy, 2017, 3 (2) : 297 - 316
  • [5] Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis
    Oba, Yuji
    Chandran, Arul V.
    Devasahayam, Joe V.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 13 (06) : 677 - 685
  • [6] Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β2-agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis
    Su, Vincent Yi-Fong
    Ding, Ting-Lin
    Chang, Yuh-Lih
    Chou, Yueh-Ching
    Hwang, Hsuen-En
    Chou, Chian-Ying
    Hsu, Chia-Chen
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, : 157 - 164
  • [7] Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for COPD: A systematic review and meta-analysis
    Horita, Nobuyuki
    Miyazawa, Naoki
    Tomaru, Koji
    Inoue, Miyo
    Kaneko, Takeshi
    RESPIROLOGY, 2015, 20 (08) : 1153 - 1159
  • [8] EFFICACY AND SAFETY OF LONG-ACTING BETA AGONISTS plus LONG ACTING MUSCARINIC ANTAGONISTS VS. LONG-ACTING BETA AGONISTS plus INHALED CORTICOSTEROIDS IN COPD: A META-ANALYSIS
    Villalobos, R. E.
    David-Wang, A.
    Magallanes, J.
    RESPIROLOGY, 2016, 21 : 177 - 177
  • [9] EFFICACY AND SAFETY OF LONG-ACTING BETA AGONISTS plus LONG ACTING MUSCARINIC ANTAGONISTS VS. LONG-ACTING BETA AGONISTS plus INHALED CORTICOSTEROIDS IN COPD: A META-ANALYSIS
    Villalobos, R. E.
    David-Wang, A.
    Magallanes, J.
    THORAX, 2016, 71 : A113 - A114
  • [10] ADHERENCE TO CURRENT GUIDELINES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SUBJECTS TREATED WITH COMBINATION OF LONG-ACTING B2-AGONIST (LABA), LONG-ACTING MUSCARINIC ANTAGONIST (LAMA) OR INHALED CORTICOSTEROIDS (ICS)
    Asche, C.
    Leader, S.
    Plauschinat, C.
    Raparla, S.
    Ye, X.
    Yan, M.
    Young, D.
    VALUE IN HEALTH, 2011, 14 (07) : A492 - A492
12345